FILE PHOTO: A logo of China's vaccine specialist CanSino Biologics Inc is pictured on the company's headquarters in Tianjin, following an outbreak of the coronavirus disease , China August 17, 2020. REUTERS/Thomas Peter/File PhotoBEIJING: Chinese researchers plan to study using a COVID-19 vaccine from CanSino Biologics as a booster shot for people who have already been inoculated with other vaccines, clinical trial registration data showed.
China has not yet approved mixing doses of different vaccines using different technologies, but the director of the Chinese Center for Disease Control and Prevention said in April the country was considering it as a way of boosting vaccine efficacy.Five out of the seven vaccines used in China's inoculation campaign are inactivated, meaning they use a coronavirus that cannot replicate in human cells. These include the Sinovac shot and two vaccines from Sinopharm.
CanSinoBIO's shot uses a modified common cold virus known as adenovirus type-5 to carry genetic material from the coronavirus protein into the body.Some participants who have received either one or two doses of inactivated vaccine will receive a booster shot from CanSinoBIO. The rest will be given the Sinovac vaccine as a booster for comparison.
The disease control authorities in Jiangsu are also running a trial that mixes doses produced by CanSinoBIO and a unit of Chongqing Zhifei Biological Products.
One of the top two vaccine makers: CanSino and Moderna. The next tier is: Sinovac and Sputnik V. Pfizer, J & J, AstraZeneca are a joke and poor copies of the original 4 mentioned above. CanSino and Moderna worked together on the vaccine since 20 Jan. 2020. Pfizer 30 Aug 2020. 😂
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »